Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Actelion CEO Seeks To Rebuild Investor Confidence As Pressure Builds On Tracleer

Executive Summary

CEO Jean-Paul Clozel is seeking to rebuild investor confidence in the wake of the company's year-long run-in with activist shareholder Elliott Advisors.

You may also be interested in...



Can Actelion Founder Clozel Recreate Another Top Biotech Post-J&J Sale?

Actelion's M&A deal with J&J vindicates the strategy of cardiologist Jean-Paul Clozel, who co-founded the Swiss firm with his wife Martine and friends in 1997, and positions him for another shot at biotech success.

Actelion Braces For Tracleer Patent Cliff With New Drugs, New Data Standards

Actelion is preparing for the patent loss on its leading PAH drug not simply with a new product, but by setting a new efficacy standard across the entire PAH community.

Actelion And Bayer Hope Novel Drugs Can Take Over The Pulmonary Hypertension Market

Impressive Phase III trial data on Actelion’s macitentan and Bayer’s riociguat generated big noises at the annual meeting of the American College of Chest Physicians in Atlanta and should support regulatory filings for the two therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS053924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel